A library of thiosemicarbazide derivatives of isoniazid 3-27, was synthesized and evaluated for their anti-inflammatory and urease inhibition activities, by using in vitro bioassays. Among these compounds 9, 10, 12, 21, and 26 were identified as new derivatives. Prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs) and infections caused by Helicobacter pylori (ureolytic bacteria), are the two most significant causes of gastric and peptic ulcers. We focused on the identification of the dual inhibitors of inflammation and urease enzyme. Compound 23 was identified as the best dual inhibitor of inflammation (ROS; IC 50 = 12.3 µg/mL), and urease enzyme inhibition activity (IC 50 = 22.4 µM). Many of these compounds showed comparable activities to the standard anti-inflammatory drug (ibuprofen, IC 50 = 11.2 µg/mL) and urease inhibitor (thiourea/acetohydraoxamic acid, IC 50 = 21.1/20.3 µM). Compound 12 was found to be the most potent urease inhibitor (IC 50 = 12.3 µM) and good inhibitor of inflammation (IC 50 = 27.7 µg/mL). Compounds 19, 11, 13, 9, 17, 10, and 16, were also found to be potent inhibitors of urease. Cytotoxicity was also evaluated and all the compounds were found to be noncytotoxic, except compound 18 and the parent drug isoniazid (IC 50 = 29.5 and 28.5 µM, respectively).
A Medicinal Chemistry Approach of Drug Discovery. Drug development is a time-intensive, costly, and high-risk process. One approach that has attracted a lot of attention in modern drug discovery is drug repositioning or repurposing 16 . Drug repurposing include cases in which a current drug, endorsed by an administrative organization for a particular disease, is found to have effect against another illness. Conversely, drug repositioning also depicts a condition where a drug that is in use for a disease is utilized as a template for the synthesis of new analogs possessing activity against another disease 17 . Drug repositioning thus essentially shorten the drug development process and thus decrease the discovery cost 18 . Current study describes the repositioning of isoniazid, an anti-bacterial agent. Isoniazid, was synthesized in 1952 for the treatment of tuberculosis 19 . The recommended daily dose of isoniazid is from 5-300 mg/day, which rarely causes side effects in individuals 20 . The use of isoniazid as the main scaffold for the synthesis of medicinally important compounds is well known as reported in the literature [21] [22] [23] [24] (Fig. 3) . Therefore, we have randomly synthesized the library of compounds followed by random screening against various biological targets. It was observed that some of these compounds are the significant dual inhibitors of inflammation, and urease. The structural similarity of synthesized compounds with the pyridine based anti-ulcer drug pantoprazole 23 , and anti-inflammatory drug etoricoxib 25 may be the reason for the activities of these compounds (Fig. 4 ). During the current study, we have synthesized thiosemicarbazide derivatives of isoniazid through modification at terminal NH 2 (Fig. 5 ) by reacting with different isothiocyanates. Thiosemicarbazide class of compounds possess the diverse biological activities, such as anti-cancer 26 , anti-fungal 27 , anti-helminthic 28 , anti-bacterial 29 and anti-HIV 30 . Among synthesized compounds, all were identified as previously known [31] [32] [33] [34] [35] [36] [37] [38] , except 9, 10, 12, 21, and 26. However, these compounds have not been reported as the dual inhibitor of inflammation and urease. Cytotoxicity of these compounds were also evaluated against 3T3 mouse fibroblast cell line. C-NMR spectroscopy. Among synthesized compounds, 9, 10, 12, 21, and 26 were found to be new.
Structure Elucidation of Representative Compound 4.
The structure elucidation of the synthesized thiosemicarbazide derivatives was performed through various spectroscopic techniques (MS, NMR, and IR). Structure elucidation of compound 4, a representative member of the library, is presented in Fig. 7 .
Singlets of protons attached to nitrogen were at δ10.93, 10.02, and 9.82. A doublet at δ 8.76 showed two protons of pyridine ring i.e. H-3″, H-5″ which are coupled with H-2″, H-6″ (J 3″,2″ = J 5″,6″ = 6 Hz). A distorted singlet at δ 7.83 represented another two protons of pyridine ring i.e. H-2″, and H-6″. Doublet appeared at δ 7.56 showed H-4 of phenyl ring, coupled with the H-5, with ortho coupling (J 4,5 = 7.8 Hz), while triplet at δ 7.36 showed a proton of phenyl ring i.e.H-5 which is coupled with H-4 and H-6 with coupling constant (J 5(4-6) = 7.8 Hz). H-6 proton of phenyl ring showed a distorted singlet at δ 7.32.
The conformation of the synthesized compound was deduced based on key 2D NOESY correlations (Fig. 7) . NH (δ9.82, singlet) showed correlations with the H-6 phenyl ring proton (δ7.32, distorted singlet), and NH www.nature.com/scientificreports www.nature.com/scientificreports/ (δ10.93, singlet). On the other hand, proton attached to nitrogen NH (δ10.02, singlet) showed correlation with pyridine ring H-6″ (δ7.83, distorted singlet). 13 C NMR spectrum of compound 4 showed five characteristic peaks of quaternary carbons at δ182.0 (C=S), 165.0 (C=O), 140.0 (C-1″), 139.3 (C-1) and 132.1, 131.0 (C-2, C-3). C-3″, C-5″ and C-2″, C-6″ of pyridine ring were resonated at δ150.6 and 121.7, while C-4 and C-5 of phenyl ring were resonated at δ 128.6 and 127.5, respectively. C-6 of phenyl ring appeared at δ 129.9. The HRFAB-MS (+ve mode) was observed at m/z 341.0017 correlating with the molecular formula [(C 13 Indeed, the inhibition showed by all the synthesized analogues is due to the mutual participation of all parts of the molecule. However, it is also true that there are some characteristic features, which play an important role in the biological activity. As depicted in the Fig. 8 the current library has only aryl part (R) which is varying. Therefore, only the limited structure activity relationship can be drawn by comparing the position and nature of the substituents present in the aryl part of thiosemicarbazide derivatives .
The compound 24 with no substituents on aryl part showed the lowest activity (IC 50 = 63.2 ± 2.0 µM) as compared to other members of the library. Substitution of bromo group at the C-3 position as in compound 22 enhances the activity with IC 50 = 22.1 ± 1.91 µM. While changing the position of bromo group to the C-2 position as in compound 14, slightly reduces the activity (IC 50 = 35.8 ± 1.8 µM).
Substitution of chloro group at the C-4 position as in compound 18 showed almost similar activity with the (IC 50 = 26.3 ± 1.59 µM). Compound 4 possess the two chloro groups at C-2 and C-3 positions and compound 5 with the chloro groups at C-2 and C-5 positions showed reduced activity with the IC 50 values 38.8 ± 0.35 µM and 36.5 ± 0.14 µM, respectively. The compound with bromo substitution at C-3 position was found to be more efficient in the inhibitory potential as compared to the chloro substituted analogues, similar effect has also been reported by ali. et al. 
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. Incorporation of the chloro and trifluoromethyl group in compound 9 have further enhanced the activity with IC 50 = 14.2 ± 1.38 µM.
Compound 11 is a para substituted derivatives (IC 50 = 13.2 ± 1.64 µM), which posses an electron withdrawing trifluoromethoxy group, showed comparable activity with compound 10 (IC 50 = 15.7 ± 1.32 µM) having the cyano group, while compound 20 (IC 50 = 22.0 ± 1.1 µM) having the electron donating methoxy group showed less activity than the compounds 11 and 10. It demonstrates that the electron withdrawing groups have the profound effect on inhibitory potential.
From the limited structure activity relationship, it can be summarized that the nature and position of the substituent both are equally responsible for demonstrating the inhibitory activity.
In Vitro Anti-inflammatory Activity. All synthesized derivatives of isoniazid (1) were also evaluated for their anti-inflammatory activity using oxidative burst assay. The standard inhibitor used was ibuprofen (IC 50 = 11.2 ± 1.9 µg/mL). Among all the compounds, compounds 23, 5, 22, 26, 9, 12, 16, and 17 showed promising anti-inflammatory activities with IC 50 value 12.3 ± 1.2 to 36.9 ± 3.0 µg/mL, while other compounds were found inactive (Table 1) .
Among these compounds, compound 23 containing a cyclohexyl ring was found to be the most active inhibitor of ROS (IC 50 = 12.3 ± 1.2 µg/mL). Compound 5 bearing chloro groups at C-2 and C-5 positions showed a good activity with an IC 50 value 18.5 ± 1.0 µg/mL, while with a bromo group at C-3, compound 22 was also found to be a good inhibitor but less active than compound 5 (IC 50 = 25.1 ± 0.4 µg/mL). On the other hand, compound 26 with a isothiocyanate group at C-3 showed the similar activity (IC 50 = 25.4 ± 1.3 µg/mL) as that of compound 5. Compound 9 with a chloro group at C-4 and trifluoromethyl group at C-3 also showed a good activity (IC 50 = 26.7 ± 2.5 µg/mL), along with this pentaflouro containing phenyl ring analogue 12 which resulted in decrease of activity from IC 50 values 26.7 ± 2.5 to 27.7 ± 2.4 µg/mL. Interestingly the mono substituted analogue of fluorine at C-3 (compound 16) showed a decreased activity with IC 50 value 29.7 ± 1.7 µg/mL, while the iodine containing analogue at C-3 (compound 17) showed further decreased activity (IC 50 = 36.9 ± 3.0 µg/mL). (1) were evaluated for their cytotoxicity against 3T3 normal (mouse fibroblast) cell lines in which all derivatives were found to be inactive, except compound 18 and isoniazid (1) which showed IC 50 values of 29.5 ± 1.9, and 28.5 ± 1.2 µM, respectively, in comparison to the standard cyclohexamide (IC 50 = 0.8 ± 1.9 µM) ( Table 1) .
Discussion
The present research study indicates that thiosemicarbazides 3-27 possess promising urease inhibition activity, as well as significant anti-inflammatory activities. Compounds 5, 9, 12, 16, 17, 22, 23, and 26 were found to be the dual inhibitors of inflammation (ROS) and urease, few members of the current library have been reported as urease inhibitors by Ali. et al. 34 but here we report the dual inhibitors of urease and inflammation along with its cytoxicity profile against 3T3 mouse fibroblast cell line. The limited SAR concludes that the compound 23 with the cyclohexyl ring was found to be the most significant dual inhibitor of urease and inflammation (IC 50 = 22.4 ± 1.83 µM and 12.3 ± 1.2 µg/mL, respectively). This showed comparable activity to the clinically used anti-inflammatory drug ibuprofen (IC 50 = 11.2 ± 1.9 µg/mL), and urease inhibitor acetohyroxamic acid (IC 50 = 20.3 ± 1.9 µg/mL). Compound 12, is the pentafluoro substituted analogue. Compound 12 was identified as the most potent inhibitor of urease (IC 50 = 12.3 ± 1.04 µM) and significant inhibitor of inflammation (IC 50 = 27.7 ± 2.4 µg/mL).
Whereas compounds 10, 11, and 13 were identified as potent inhibitors of urease enzyme, however, these compounds were found to be inactive in anti-inflammatory assay. The SAR clearly shows that change in the substituents and its positions or changing the aryl ring by the alkyl ring greatly affects the biological activity of the synthesized compounds.
In conclusion, the compounds reported here may serve as the starting points for the designing and development of new and powerful dual inhibitors of inflammation and infections caused by ureolytic bacteria. is the standard error of the mean, SD b is the standard deviation, and Insoluble d refers to those analogue which are partially soluble in HPLC methanol used in the protocol of in vitro urease inhibition activity. Compounds showed <50% inhibition were considered as inactive. For Urease enzyme inhibition activity, screening concentration was 0.5 mM. For ROS inhibition assay screening concentration was 25 µg/mL. Note: All data were presented as mean ± standard deviation/standard error of the mean of three independent experiments where each sample was run in triplicate. The IC 50 values were obtained using three concentrations of test compound, and were calculated using Excel Based Program. Precoated silica gel plates (ALUGRAM, SIL G/UV254) were used for thin layer chromatography (TLC). TLC chromatograms were viewed under the ultraviolet light of 254 and 365 nm. Electron impact mass spectroscopy (EI-MS) and Fast atom bombardment direct probe mass spectra (FAB-MS) were obtained through JEOLJMS-600H mass spectrometer (Japan).
1 H and 13 C-NMR spectra were performed on a 300, 400, and 100 MHz Bruker Avance spectrometers (Switzerland). Buchi M-560 apparatus was used for recording the melting point (Japan). I. R. Spectrophotometry of the compounds was performed on FTIR-8900 (Shimadzu, Japan) through KBr disc.
General Procedure of the Synthesis of Compounds 3-27.
Isoniazid (1) (2 mmol) was refluxed with methanol (10 mL) for 15 minutes. Corresponding isothiocyanate (2 mmol) was added, and kept on stirring for 8-10 hours at room temperature (25 °C). Reaction progress was examined by TLC (7.9: 2: 0.1) (ethyl acetate, methanol and acetic acid) analysis. Disappearance of starting material from reaction mixture indicated the completion of reaction. The reaction mixture was concentrated under reduced pressure, solid product thus obtained was purified through solvent-solvent extraction with the help of hexane and ethyl acetate, and then recrystallized from methanol. Among these compounds, 9, 10, 12, 21, and 26 were identified as new derivatives. The known compounds were found to be spectroscopically similar to that reported in the literature. 95 (s, 1 H, NH), 10.11 (s, 1 H, NH), 9.47 (s, 1 H, NH), 8.75 (d, J 3″,2″ = J 5″,6″ = 4.8 Hz, 2 H, H-3″, H-5″), 7.84  (distorted singlet, 2 H, H-2″, H-6″), 7.34 (m, 1 H, H-4), 7.12 (t, J 3,2/3,4 = J 5,4/5,6 8.0 Hz, 2 H, H-3, H-5) ; 91 (s, 1 H, NH), 10.0 (s, 1 H, NH), 9.61 (s,1 H, NH), 8.75 (d, J 3″ ,2″ = J 5″,6″ = 4.8 Hz, 2 H, H-3″, H-5″), 7.83 (s, 2 H, H-2″, H-6″), 7.26 (t, J 5,6 = J 6,5 = 8.4 Hz, 2 H, H-6, H-5), 7.00 (t, J 3(4,2) = 8. 
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